

Cover Story
After a courtroom victory against Amgen Inc. this summer, the last of the obstacles was removed for the first biosimilar agent—a white blood cell growth factor—to enter the U.S. market.
By Matthew Bin Han Ong
By Matthew Bin Han Ong
In Brief
Drugs & Targets


Trending Stories
- Nancy Goodman: “Sen. Sanders says he cares about kids with cancer. I’m just asking him to show us.”
- House passes three-year extension of ACA subsidies with bipartisan support
- Elisa Rodriguez named first chief diversity and equity officer for faculty at Roswell Park
- Gregory Curt, Clinician and Drug Developer, Dies at 64
- Mikaela Naylon Give Kids a Chance Act nixed by Senate
- Klausner: CRUK Grand Challenge—more than just another grant











